ArticleThe Journal of clinical endocrinology and metabolism2019
Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
Article in The Journal of clinical endocrinology and metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of sequential treatment strategies for osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Pooled it
- Longitudinal osteoporosis therapy: treat-to-target and sequential strategies-a narrative review.Therapeutic advances in musculoskeletal disease · 2026Review
- Real-world effectiveness of denosumab compared to teriparatide in patients with severe osteoporosis.Frontiers in endocrinology · 2026Article
- Fractures in Parkinson's Disease: Pathophysiology, Prevention, and Orthopedic Outcomes.Cureus · 2025Review
- Risk assessment and drug interruption guidelines for dentoalveolar surgery in patients with osteoporosis receiving anti-resorptive therapy.Journal of dental sciences · 2025Review
- MTX Osteopathy Versus Osteoporosis Including Response to Treatment Data-A Retrospective Single Center Study Including 172 Patients.Calcified tissue international · 2024Article
- The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part II.Journal of menopausal medicine · 2024Review
- Asia-Pacific consensus on long-term and sequential therapy for osteoporosis.Osteoporosis and sarcopenia · 2024Review
- Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience.International journal of endocrinology · 2023Article
- Recent advances in the identification of related factors and preventive strategies of hip fracture.Frontiers in public health · 2023Review
- Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment.Journal of clinical medicine · 2022Article
- Effect of denosumab on renal function in women with osteoporosis evaluated using cystatin C.Osteoporosis and sarcopenia · 2022Article
- Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review.Advances in therapy · 2022Review
- Skeletal outcomes of patients with osteogenesis imperfecta during drug holiday of bisphosphonates: a real-world study.Frontiers in endocrinology · 2022Article
- Osteoporosis in 10 years time: a glimpse into the future of osteoporosis.Therapeutic advances in musculoskeletal disease · 2022Article
- Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021Article
- Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives.Frontiers in pharmacology · 2020Review
- Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.The Journal of clinical endocrinology and metabolism · 2019Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
contextTeriparatide and denosumab are effective treatments for osteoporosis and typically reserved as second-line options after patients have used bisphosphonates. However, limited head-to-head comparative effectiveness data exist between teriparatide and denosumab.
objectiveWe compared changes in bone mineral density (BMD) between groups treated with teriparatide or denosumab after using bisphosphonates, focusing on the change in BMD while on either drug over 2 years.
designObservational cohort study using electronic medical records from two academic medical centers in the United States.
participantsThe study population included osteoporotic patients >45 years who received bisphosphonates >1 year before switching to teriparatide or denosumab. OUTCOME MEASURES: Annualized BMD change from baseline at the lumbar spine, total hip, and femoral neck.
resultsPatients treated with teriparatide (n = 110) were compared with those treated with denosumab (n = 105); the mean (SD) age was 70 (10) years and median duration (interquartile range) of bisphosphonate use was 7.0 (5.6 to 9.7) years. Compared with denosumab users, teriparatide users had higher annualized BMD change at the spine by 1.3% (95% CI 0.02, 2.7%) but lower at the total hip by -2.2% (95% CI -2.9 to -1.5%) and the femoral neck by -1.1% (95% CI -2.1 to -0.1%). Those who switched to teriparatide had a transient loss of hip BMD for the first year, with no overall increase in the total hip BMD over 2 years.
conclusionsAmong patients who use long-term bisphosphonates, the decision of switching to teriparatide should be made with caution, especially for patients at high risk of hip fracture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.